Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab

Trial Profile

Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms PETACC-8
  • Most Recent Events

    • 20 Jan 2018 Results from patients receiving adjuvant FOLFOX in MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials (n=7230) presented at the 2018 Gastrointestinal Cancers Symposium
    • 06 Jun 2017 Results of clinical utility of colon cancer molecular subtypes presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results (n=1869) assessing prognostic value of primary location and its relationship to MSI, RAS and BRAF mutational status, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top